openPR Logo
Press release

Dementia Market 2032: Epidemiology Data, Pipeline Breakthroughs, Regulatory Landmarks by DelveInsight | Charsire Biotech, ProNeurogen Therapeutics, Resverlogix, Cyclerion Therapeutics, CSPC-NBP

05-10-2024 02:56 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Dementia Market 2032: Epidemiology Data, Pipeline

The Dementia Market size was valued approximately USD 21 million in 2021 and the report offers an in-depth understanding of the Dementia, historical and forecasted epidemiology as well as the Dementia market trends in the 7MM.
DelveInsight's "Dementia Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Dementia, historical and forecasted epidemiology as well as the Dementia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Dementia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dementia Market Forecast [https://www.delveinsight.com/sample-request/dementia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Dementia Market Report:

*
The Dementia market size was valued approximately USD 21 million in 2021 and is anticipated to grow with a significant CAGR of 2.42% during the study period (2019-2032)

*
In 2022, the estimated total prevalence of dementia cases across the 7MM was 22,112,602, with a projected Compound Annual Growth Rate (CAGR) expected to be notably higher during the study period.

*
In 2022, there were 11,751,680 diagnosed cases of dementia identified in the 7MM, with expectations of further increases during the study period spanning from 2019 to 2032.

*
As per the Centers for Disease Control and Prevention (2022), Alzheimer's disease stands as the predominant form of dementia. Current statistics suggest approximately 5.8 million individuals in the United States are affected by Alzheimer's disease and related dementias, comprising 5.6 million individuals aged 65 and above, and roughly 200,000 individuals under 65 with early-onset Alzheimer's.

*
According to Dementia UK (2023), the estimated number of people living with dementia in the UK surpasses 900,000 individuals.

*
Key Dementia Companies: EIP Pharma Inc, Sun Pharma Advanced Research Company Limited, Pfizer, Allyx Therapeutics, BioXcel Therapeutics Inc, Prevail Therapeutics, Eli Lilly and Company, Cerevel Therapeutics, LLC, Cognition Therapeutics, Alector Inc., Athira Pharma, Otsuka Pharmaceutical Development & Commercialization, Inc., Karuna Therapeutics, CuraSen Therapeutics, Inc., Passage Bio, Inc., Suven Life Sciences Limited, Biogen, Sage Therapeutics, Transposon Therapeutics, Inc., Axsome Therapeutics, Inc., Janssen Research & Development, LLC, TrueBinding, Inc., Merck Sharp & Dohme LLC, Cassava Sciences, Inc., BioVie Inc., Vivoryon Therapeutics N.V., Alnylam Pharmaceuticals, and others

*
Key Dementia Therapies: Neflamapimod, K0706, Bosutinib, BMS-984923, BXCL501, PR006, CVL-871, CT1812, AL001, ATH-1017, AVP-786, KarXT, CST-2032, PBFT02, Masupirdine, BIIB080, SAGE-718, TPN-101, AXS-05, JNJ-63733657, Donanemab, TB006, MK-2214, Simufilam, NE3107, Aducanumab, PQ912, SAGE-718, ALN-APP, and others

*
The Dementia epidemiology based on age-specific cases analyzed that Dementia (VaD) is highly prevalent in age group of 60 years and above, while below this age group the disease appears to be rare

*
The Dementia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dementia pipeline products will significantly revolutionize the Dementia market dynamics.

Dementia Overview

An etiological category of dementia known as Dementia (VaD) is defined by significant cognitive impairment brought on by an ischemia or hemorrhagic stroke or by hypoperfusion of brain areas crucial for memory, cognition, and behavior.

Get a Free sample for the Dementia Market Report:

https://www.delveinsight.com/report-store/dementia-market [https://www.delveinsight.com/report-store/dementia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Dementia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Dementia Epidemiology Segmentation:

The Dementia market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

*
Total Prevalence of Dementia

*
Prevalent Cases of Dementia by severity

*
Gender-specific Prevalence of Dementia

*
Diagnosed Cases of Episodic and Chronic Dementia

Download the report to understand which factors are driving Dementia epidemiology trends @ Dementia Epidemiology Forecast [https://www.delveinsight.com/sample-request/dementia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Dementia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dementia market or expected to get launched during the study period. The analysis covers Dementia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Dementia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Dementia Therapies and Key Companies

*
Neflamapimod: EIP Pharma Inc

*
K0706: Sun Pharma Advanced Research Company Limited

*
Bosutinib: Pfizer

*
BMS-984923: Allyx Therapeutics

*
BXCL501: BioXcel Therapeutics Inc

*
PR006: Prevail Therapeutics/Eli Lilly and Company

*
CVL-871: Cerevel Therapeutics, LLC

*
CT1812: Cognition Therapeutics

*
AL001: Alector Inc.

*
ATH-1017: Athira Pharma

*
AVP-786: Otsuka Pharmaceutical Development & Commercialization, Inc.

*
KarXT: Karuna Therapeutics

*
CST-2032: CuraSen Therapeutics, Inc.

*
PBFT02: Passage Bio, Inc.

*
Masupirdine: Suven Life Sciences Limited

*
BIIB080: Biogen

*
SAGE-718: Sage Therapeutics

*
TPN-101: Transposon Therapeutics, Inc.

*
AXS-05: Axsome Therapeutics, Inc.

*
JNJ-63733657: Janssen Research & Development, LLC

*
Donanemab: Eli Lilly and Company

*
TB006: TrueBinding, Inc.

*
MK-2214: Merck Sharp & Dohme LLC

*
Simufilam: Cassava Sciences, Inc.

*
NE3107: BioVie Inc.

*
Aducanumab: Biogen

*
PQ912: Vivoryon Therapeutics N.V.

*
SAGE-718: Sage Therapeutics

*
ALN-APP: Alnylam Pharmaceuticals

Discover more about therapies set to grab major Dementia market share @ Dementia Treatment Market [https://www.delveinsight.com/sample-request/dementia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Dementia Market Strengths

*
The increasing prevalent population in the 7MM is likely to cause an upsurge in treatment need. Consequently, with successful launch of emerging therapies, the market will witness a boost in the upcoming year.

Dementia Market opportunities

*
Medications with better safety and effectiveness, which provide optimum care are the current unmet need of the VaD disease market.

Scope of the Dementia Market Report

*
Study Period: 2019-2032

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Dementia Companies: EIP Pharma Inc, Sun Pharma Advanced Research Company Limited, Pfizer, Allyx Therapeutics, BioXcel Therapeutics Inc, Prevail Therapeutics, Eli Lilly and Company, Cerevel Therapeutics, LLC, Cognition Therapeutics, Alector Inc., Athira Pharma, Otsuka Pharmaceutical Development & Commercialization, Inc., Karuna Therapeutics, CuraSen Therapeutics, Inc., Passage Bio, Inc., Suven Life Sciences Limited, Biogen, Sage Therapeutics, Transposon Therapeutics, Inc., Axsome Therapeutics, Inc., Janssen Research & Development, LLC, TrueBinding, Inc., Merck Sharp & Dohme LLC, Cassava Sciences, Inc., BioVie Inc., Vivoryon Therapeutics N.V., Alnylam Pharmaceuticals, and others

*
Key Dementia Therapies: Neflamapimod, K0706, Bosutinib, BMS-984923, BXCL501, PR006, CVL-871, CT1812, AL001, ATH-1017, AVP-786, KarXT, CST-2032, PBFT02, Masupirdine, BIIB080, SAGE-718, TPN-101, AXS-05, JNJ-63733657, Donanemab, TB006, MK-2214, Simufilam, NE3107, Aducanumab, PQ912, SAGE-718, ALN-APP, and others

*
Dementia Therapeutic Assessment: Dementia current marketed and Dementia emerging therapies

*
Dementia Market Dynamics: Dementia market drivers and Dementia market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Dementia Unmet Needs, KOL's views, Analyst's views, Dementia Market Access and Reimbursement

To know more about Dementia companies working in the treatment market, visit @ Dementia Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/dementia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Dementia Market Report Introduction

2. Executive Summary for Dementia

3. SWOT analysis of Dementia

4. Dementia Patient Share (%) Overview at a Glance

5. Dementia Market Overview at a Glance

6. Dementia Disease Background and Overview

7. Dementia Epidemiology and Patient Population

8. Country-Specific Patient Population of Dementia

9. Dementia Current Treatment and Medical Practices

10. Dementia Unmet Needs

11. Dementia Emerging Therapies

12. Dementia Market Outlook

13. Country-Wise Dementia Market Analysis (2019-2032)

14. Dementia Market Access and Reimbursement of Therapies

15. Dementia Market Drivers

16. Dementia Market Barriers

17. Dementia Appendix

18. Dementia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=dementia-market-2032-epidemiology-data-pipeline-breakthroughs-regulatory-landmarks-by-delveinsight-charsire-biotech-proneurogen-therapeutics-resverlogix-cyclerion-therapeutics-cspcnbp]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Dementia Market 2032: Epidemiology Data, Pipeline Breakthroughs, Regulatory Landmarks by DelveInsight | Charsire Biotech, ProNeurogen Therapeutics, Resverlogix, Cyclerion Therapeutics, CSPC-NBP here

News-ID: 3492797 • Views:

More Releases from ABNewswire

New Report: The Top 5 Places Seniors Have Hidden Unclaimed Property
New Report: The Top 5 Places Seniors Have Hidden Unclaimed Property
Recovering even one of these hidden assets could cover prescriptions, travel, or a grandchild's college savings. Many seniors sit on lost money they could reclaim right now by finding their unclaimed property. These five overlooked assets often hold more value than you might think. Recovering them can provide an income boost, and doing so doesn't have to be hard. 1. Life Settlement A life settlement converts a no-longer-needed policy into cash. A buyer
Alcoholic Hepatitis Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Durect Corporation, Novartis, Intercept Pharmaceuticals, Immuron Ltd., Gilead Sciences
Alcoholic Hepatitis Market to Evolve Rapidly Over the Next Decade by 2034, Delve …
The Key Alcoholic Hepatitis Companies in the market include - Durect Corporation, Novartis, Intercept Pharmaceuticals, Immuron Ltd., Gilead Sciences, Hoffmann-La Roche, Cellaion SA, and others. DelveInsight's "Alcoholic Hepatitis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Alcoholic Hepatitis, historical and forecasted epidemiology as well as the Alcoholic Hepatitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in
Vitiligo Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Pfizer, Clinuvel, Inc., Clinuvel Pharmaceuticals, Bioniz Therapeutics, TAGCyx Biotech
Vitiligo Market Positioned for Accelerated Development Through 2034, DelveInsigh …
The Key Vitiligo Companies in the market include - Incyte, Abbvie, Pfizer, Clinuvel, Inc., Clinuvel Pharmaceuticals, Bioniz Therapeutics, TAGCyx Biotechnologies, Temprian Therapeutics, Aclaris Therapeutics, TWi Biotechnology, Dermavant Sciences, Amgen, Pfizer, Incyte Corporation, and others. The Vitiligo market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Vitiligo pipeline products will significantly revolutionize the Vitiligo market dynamics. DelveInsight's "Vitiligo Market Insights, Epidemiology,
Keratoconus Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | CooperVision, Optik Seis, SAFILENS S.R.L, Novartis, CIBA VISION, Menicon
Keratoconus Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Keratoconus pipeline constitutes 3+ key companies continuously working towards developing 3+ Keratoconus treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Keratoconus Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/keratoconus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Keratoconus Market. The Keratoconus Pipeline report embraces in-depth commercial and clinical

All 5 Releases


More Releases for Dementia

Revolutionising Dementia Care: Psychology World and Dementia India Alliance Unve …
Revolutionising Dementia Care: Psychology World and Dementia India Alliance Unveil New Training Course As India faces a growing dementia crisis, Psychology World and the Dementia India Alliance (DIA) have joined forces to launch a new Dementia Orientation Certificate Course designed specifically for healthcare workers. The course, introduced on World Mental Health Day, aims to address the dual challenges of providing quality care for dementia patients and supporting the mental health of
Empowering Growth: Dementia Diagnosis App Market 2024 and Industry Segments Expl …
Growing Demand of the Dementia Diagnosis App Market Overview 2024-2032: The latest release from Infinity Business Insights titled Dementia Diagnosis App Market Research Report 2024-2032 (by Product Type, End-User / Application, and Regions / Countries) provides an in-depth assessment of the Dementia Diagnosis App including key market trends, upcoming technologies, industry drivers, challenges, regulatory policies, key players company profiles, and strategies. Global Dementia Diagnosis App Market study with 100+ market data
Frontotemporal Dementia Treatment Market - Empathy in Action: Pioneering Frontot …
Newark, New Castle, USA: The "Frontotemporal Dementia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Frontotemporal Dementia Treatment Market: https://www.growthplusreports.com/report/frontotemporal-dementia-treatment-market/8569 This latest report researches the industry structure,
Dementia Care APP Market Analysis 2023 Global Future Outlook 2028, Key Applicati …
Dementia Care APP Market is segmented by Type, by region, by profile, and by Application. This Report holds market analysis, growth, slopes, forecast, and complete strategies in the future. It also guides with planned and organized choices that include the necessary information to perform PEST, SWOT, and STEER analysis. Moreover, the Dementia Care APP Market report analyses the vital performance and operational metrics so that you can plan robust business
Dementia Care APP Market Is Booming Worldwide 2021-2027 | Dementia Digital Diary …
Global Dementia Care APP market 2020-2026 in-depth study accumulated to supply latest insights concerning acute options. The report contains different predictions associated with Dementia Care APP market size, revenue, production, CAGR, consumption, profit margin, price, and different substantial factors. Whereas accentuation the key driving and Dementia Care APP restraining forces for this market, the report offers trends and developments. It additionally examines the role of the leading
Dementia Treatment
Dementia Drugs and Treatment Market describes its growth, size, share, Forecast and trends to 2025 The global Dementia Drugs and Treatment market is valued at 13900 million US$ in 2018 is expected to reach 26500 million US$ by the end of 2025, growing at a CAGR of 8.4% during 2019-2025. This report focuses on Dementia Drugs volume and value at global level, regional level and company level. From a global perspective, this